Deprescribing: what is it and what does the evidence tell us? - PubMed (original) (raw)

Deprescribing: what is it and what does the evidence tell us?

Wade Thompson et al. Can J Hosp Pharm. 2013 May.

No abstract available

PubMed Disclaimer

Similar articles

• Deprescribing recommendations: An essential consideration for clinical guideline developers.
  Moriarty F, Pottie K, Dolovich L, McCarthy L, Rojas-Fernandez C, Farrell B. Moriarty F, et al. Res Social Adm Pharm. 2019 Jun;15(6):806-810. doi: 10.1016/j.sapharm.2018.08.014. Epub 2018 Sep 18. Res Social Adm Pharm. 2019. PMID: 30241877
• Deprescribing: the emerging evidence for and the practice of the 'geriatrician's salute'.
  Hilmer SN, Gnjidic D. Hilmer SN, et al. Age Ageing. 2018 Sep 1;47(5):638-640. doi: 10.1093/ageing/afy014. Age Ageing. 2018. PMID: 30165501
• Novel tool for deprescribing in chronic patients with multimorbidity: List of Evidence-Based Deprescribing for Chronic Patients criteria.
  Rodríguez-Pérez A, Alfaro-Lara ER, Albiñana-Perez S, Nieto-Martín MD, Díez-Manglano J, Pérez-Guerrero C, Santos-Ramos B. Rodríguez-Pérez A, et al. Geriatr Gerontol Int. 2017 Nov;17(11):2200-2207. doi: 10.1111/ggi.13062. Epub 2017 May 21. Geriatr Gerontol Int. 2017. PMID: 28544188
• [Evidence database for deprescribing of antipsychotic drugs in elderly and senile patients].
  Tkacheva ON, Ostroumova OD, Krasnov GS, Isaev RI, Kotovskaya YV. Tkacheva ON, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(5):162-172. doi: 10.17116/jnevro2019119051162. Zh Nevrol Psikhiatr Im S S Korsakova. 2019. PMID: 31317906 Review. Russian.
• Deprescribing in the Older Patient: A Narrative Review of Challenges and Solutions.
  Wu H, Kouladjian O'Donnell L, Fujita K, Masnoon N, Hilmer SN. Wu H, et al. Int J Gen Med. 2021 Jul 24;14:3793-3807. doi: 10.2147/IJGM.S253177. eCollection 2021. Int J Gen Med. 2021. PMID: 34335046 Free PMC article. Review.

Cited by

• A quantitative study on the impact of a community falls pharmacist role, on medicines optimisation in older people at risk of falls.
  Crawford P, Plumb R, Burns P, Flanagan S, Parsons C. Crawford P, et al. BMC Geriatr. 2024 Jul 15;24(1):604. doi: 10.1186/s12877-024-05189-6. BMC Geriatr. 2024. PMID: 39009970 Free PMC article.
• Methodological Challenges for Epidemiologic Studies of Deprescribing at the End of Life.
  Tjia J, Lund JL, Mack DS, Mbrah A, Yuan Y, Chen Q, Osundolire S, McDermott CL. Tjia J, et al. Curr Epidemiol Rep. 2021 Sep;8(3):116-129. doi: 10.1007/s40471-021-00264-7. Epub 2021 Apr 23. Curr Epidemiol Rep. 2021. PMID: 34722115 Free PMC article.
• Co-designing an intervention to improve the process of deprescribing for older people living with frailty in the United Kingdom.
  Silcock J, Marques I, Olaniyan J, Raynor DK, Baxter H, Gray N, Zaidi STR, Peat G, Fylan B, Breen L, Benn J, Alldred DP. Silcock J, et al. Health Expect. 2023 Feb;26(1):399-408. doi: 10.1111/hex.13669. Epub 2022 Nov 24. Health Expect. 2023. PMID: 36420768 Free PMC article.
• Deprescribing: What is the gold standard? Themes that characterized the discussions at the first Danish symposium on evidence-based deprescribing.
  Kaas Oldenburg LI, Dalin D, Drastrup AM, Vermehren C. Kaas Oldenburg LI, et al. Explor Res Clin Soc Pharm. 2022 Jan 7;5:100102. doi: 10.1016/j.rcsop.2022.100102. eCollection 2022 Mar. Explor Res Clin Soc Pharm. 2022. PMID: 35478500 Free PMC article.
• Design and analysis of longitudinal trials of antimicrobial use at the end of life: to give or not to give?
  Juthani-Mehta M, Allore HG. Juthani-Mehta M, et al. Ther Adv Drug Saf. 2019 Feb 8;10:2042098618820210. doi: 10.1177/2042098618820210. eCollection 2019. Ther Adv Drug Saf. 2019. PMID: 30800269 Free PMC article. Review.

References

1. 1. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345–51. doi: 10.1016/j.amjopharm.2007.12.002. - DOI - PubMed
2. 1. Ziere G, Dieleman JP, Hofman A, Pols HAP, Van Der Cammen TJ, Stricker BHC. Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol. 2006;61(2):218–23. doi: 10.1111/j.1365-2125.2005.02543.x. - DOI - PMC - PubMed
3. 1. Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging. 2009;26(12):1039–48. doi: 10.2165/11319530-000000000-00000. - DOI - PubMed
4. 1. Farrell B, Thompson W. The evidence for deprescribing: trials and tribulations [presentation]. Canadian Society of Hospital Pharmacists Professional Practice Conference; 2013 Feb 3–6; Toronto (ON).
5. 1. Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SN. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med. 2012;28(2):237–53. doi: 10.1016/j.cger.2012.01.006. - DOI - PubMed

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • scite Smart Citations